Mesoblast Limited (MESO) Cash Flow Statement

The OCF/NI ratio never exceeds 1.07 and sits below 0.50 in three of the eight reported quarters, which means cash absorption is largely tracking the loss-making operations rather than diverging from them. Notably, the gap between net loss and operating cash flow in those quarters is materially larger than the disclosed stock-based compensation and depreciation add-backs, which may indicate additional non-cash charges such as expensed development spend or impairment; this warrants further investigation rather than being read as a quality-of-earnings positive. The 2024Q3 and 2024Q4 operating cash line reads as zero and is treated as data unavailable, so no conversion conclusion is drawn from those periods.

Quarterly FCF ranges from -$0.04M to -$15.7M, but the wide dispersion in FCF margins, from -2.1% to -182.4%, is an artifact of lumpy milestone revenue rather than evidence of improving or deteriorating cash economics. The most recent quarters show smaller absolute outflows (-$6.9M and -$4.5M) than the -$14.9M and -$15.7M seen in 2025Q4 and 2026Q2, yet part of that apparent improvement appears to reflect working-capital timing rather than a structural reduction in operating spend. Investors should monitor whether sequential FCF burn stabilizes on an underlying royalty-only revenue base, since the current trajectory offers no evidence of convergence toward breakeven.

Only one quarter (2024Q2, +$1.9M) shows working capital contributing to cash, so the pattern suggests collections and milestone receipt timing are not being matched by payables or accrual management, or that receivables are building as revenue scales. In 2026Q4 this matters materially: the $9.0M working-capital outflow exceeds the entire -$6.7M operating cash flow, implying that without that drag the underlying cash absorption would have looked considerably smaller, and equally that reported OCF flatters the quarter's true operating economics. Because milestone payments are inherently non-recurring, the receivable build implied by these figures should be tracked closely as a test of whether reported revenue is converting to banked cash.

Excluding the two quarters with no operating cash figure, the eight reported periods show net losses of approximately $156M against operating outflows of $88M, meaning roughly $68M of the accounting loss never consumed cash. That divergence should not be read as comfort: disclosed stock-based compensation ($15.1M cumulative) and depreciation ($10.2M cumulative) explain only part of it, so the remainder likely sits in non-cash development or impairment items that signal platform value erosion even as cash survives. The structural implication is that the accounting hole and the funding hole are of different orders, and the funding hole, not the reported loss, is what constrains runway.